ArticleJournal of immunology research2026
Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveIn order to investigate the therapeutic mechanism of Jianpiyiqi Granule in juvenile myasthenia gravis (JMG) and find the immune-associated cytokines or signaling pathways targeted by this intervention.
methods(1) We extracted JMG serum samples from the sample bank of the Hebei Provincial Key Laboratory of Myasthenia Gravis before and after treatment. (2) Using Olink Immune Response Panel detects serum cytokines. Data were collated and analyzed using statistical software. Differentially expressed proteins (DEPs) were visualized using heat maps, volcano plots, and other tools. Differentially expressed cytokines were analyzed using KEGG enrichment pathway analysis to identify the relevant signaling pathways they participate in.
results(1) Twelve of 92 cytokines were found to be differentially expressed from 20 patients before and after treatment, namely AXIN1, CCL11, CCL13, CCL20, CCL25, CCL3, CD40, IL12B, S100A12, SIRT2, SLAMF1, and STAMBP (|log
conclusionsDrug therapy for JMG revealed 12 differentially expressed cytokines. Due to the exploratory nature and sample volume constraints, only two candidate cytokines were validated by ELISA. We found that the cytokines CCL11 and CCL20-associated with the IL-17 signaling pathway-were downregulated after treatment. The drug therapy may inhibit MG progression by reducing the expression of IL-17-associated cytokines. At the same time, the drug reduced the expression of CCL3, CCL13, CCL25, and CD40, which may play a role in the abnormal proliferation of thymocytes and chronic inflammatory response at the neuromuscular junction. Future studies with multiplex assays are needed to confirm the involvement of other differentially expressed cytokines, such as SIRT2 and AXIN1, which may contribute to disease mechanisms outside the identified pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.